As the first COVID-19 vaccines are rolled out around the world, HIV/AIDS experts and advocates have sought to reassure those ...
More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...
Clinical Trials Arena on MSN
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial
Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...
Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...
Review of current evidence indicates immune checkpoint inhibitors offer comparable efficacy and safety for NSCLC in people ...
A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...
A nationwide campaign in Spain is raising awareness of the labour rights of people living with HIV, while strengthening the commitment of businesses, public administrations and civil society to combat ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
The University of Houston is joining a $21.2 million statewide effort to fight the opioid epidemic.UH’s college of pharmacy received a $250,000 grant to study how opioid use ...
"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.
ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback